Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

The Role of Diabetes Care and Its Contributions to the Field of Diabetes: A Profile in Progress.

Reynolds L, Genuth SM.

Diabetes Care. 2018 Feb;41(2):241-249. doi: 10.2337/dci17-0021. No abstract available.

PMID:
29358468
2.

Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

Pop-Busui R, Braffett BH, Zinman B, Martin C, White NH, Herman WH, Genuth S, Gubitosi-Klug R; DCCT/EDIC Research Group.

Diabetes Care. 2017 Jan;40(1):94-100. doi: 10.2337/dc16-1397. Epub 2016 Nov 1.

3.
4.

Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort.

Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):E3002-11. doi: 10.1073/pnas.1603712113. Epub 2016 May 9.

5.

Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes.

Sell DR, Sun W, Gao X, Strauch C, Lachin JM, Cleary PA, Genuth S; DCCT/EDIC Research Group, Monnier VM.

Cardiovasc Diabetol. 2016 Feb 11;15:30. doi: 10.1186/s12933-016-0343-3.

6.

Data sharing is desirable, but benefits should not be exaggerated.

Nathan DM, Genuth SM, Zinman B, Lachin JM.

BMJ. 2015 Oct 21;351:h5508. doi: 10.1136/bmj.h5508. No abstract available.

PMID:
26489751
7.

Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.

Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, O'Connor PJ, Sigal RJ, Solomon S; ACCORD Investigators.

Diabetes Care. 2015 Nov;38(11):2000-8. doi: 10.2337/dc15-0598. Epub 2015 Oct 13.

8.

Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.

Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S; DCCT/EDIC Research Group.

Cardiovasc Diabetol. 2015 Oct 9;14:138. doi: 10.1186/s12933-015-0295-z. No abstract available.

9.

Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.

Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S; DCCT/EDIC Research Group.

Cardiovasc Diabetol. 2015 Sep 5;14:118. doi: 10.1186/s12933-015-0266-4. Erratum in: Cardiovasc Diabetol. 2015;14:138.

10.

Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.

Zonszein J, Lombardero M, Ismail-Beigi F, Palumbo P, Foucher S, Groenewoud Y, Cushing G, Wajchenberg B, Genuth S; Bari 2D Study Group.

J Diabetes Res. 2015;2015:129891. doi: 10.1155/2015/129891. Epub 2015 May 27.

12.
13.

Self-reported prevalence of diabetes screening in the U.S., 2005-2010.

Casagrande SS, Cowie CC, Genuth SM.

Am J Prev Med. 2014 Dec;47(6):780-7. doi: 10.1016/j.amepre.2014.07.039. Epub 2014 Sep 16.

14.

Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes.

Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J; DCCT/EDIC Research Group, Monnier VM.

Diabetes. 2015 Jan;64(1):266-78. doi: 10.2337/db14-0215. Epub 2014 Sep 3.

15.

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.

Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group.

Ophthalmology. 2014 Dec;121(12):2443-51. doi: 10.1016/j.ophtha.2014.07.019. Epub 2014 Aug 29.

16.

Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2014 Apr 22;129(16):e460-1. doi: 10.1161/CIRCULATIONAHA.113.008033. No abstract available.

PMID:
24753557
17.

Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes.

Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R; DCCT/EDIC Research Group.

Diabetes. 2014 May;63(5):1748-62. doi: 10.2337/db13-1251. Epub 2014 Jan 23.

18.

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentations.

Zinman B, Genuth S, Nathan DM.

Diabetes Care. 2014;37(1):8. doi: 10.2337/dc13-2111. No abstract available.

19.

Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions.

Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B; DCCT/EDIC Research Group.

Diabetes. 2013 Dec;62(12):3976-86. doi: 10.2337/db13-1093. No abstract available.

20.

How does pioglitazone prevent progression of impaired glucose tolerance to diabetes?

Genuth SM.

Diabetes. 2013 Nov;62(11):3663-5. doi: 10.2337/db13-1175. No abstract available.

21.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.

22.

Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications.

Monnier VM, Sun W, Sell DR, Fan X, Nemet I, Genuth S.

Clin Chem Lab Med. 2014 Jan 1;52(1):21-32. doi: 10.1515/cclm-2013-0174. Review.

23.

Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.

Orchard TJ, Sun W, Cleary PA, Genuth SM, Lachin JM, McGee P, Paterson AD, Raskin P, Anbinder Y, Levy AP; DCCT/EDIC Research Group.

Diabetes. 2013 Sep;62(9):3218-23. doi: 10.2337/db13-0256. Epub 2013 Jun 12.

24.

Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC.

Genuth SM, Backlund JY, Bayless M, Bluemke DA, Cleary PA, Crandall J, Lachin JM, Lima JA, Miao C, Turkbey EB; DCCT/EDIC Research Group.

Diabetes. 2013 Oct;62(10):3561-9. doi: 10.2337/db12-0546. Epub 2013 Mar 21.

25.

Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.

Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J; BARI 2D Study Group.

J Diabetes Complications. 2014 Jan-Feb;28(1):101-9. doi: 10.1016/j.jdiacomp.2013.01.006. Epub 2013 Mar 7.

26.

The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes.

Monnier VM, Sell DR, Strauch C, Sun W, Lachin JM, Cleary PA, Genuth S; DCCT Research Group.

J Diabetes Complications. 2013 Mar-Apr;27(2):141-9. doi: 10.1016/j.jdiacomp.2012.10.004. Epub 2012 Nov 12.

27.

Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC).

Larkin ME, Lorenzi GM, Bayless M, Cleary PA, Barnie A, Golden E, Hitt S, Genuth S.

Clin Trials. 2012 Aug;9(4):418-25. doi: 10.1177/1740774512449532. Epub 2012 Jun 22.

28.

Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, Genuth S, Cushman WC, Gerstein HC, Probstfield JL, Katz L, Schubart U; ACCORD Study Group.

Kidney Int. 2012 Mar;81(6):586-94. doi: 10.1038/ki.2011.415. Epub 2011 Dec 14.

29.

Clinical implications of the ACCORD trial.

Genuth S, Ismail-Beigi F.

J Clin Endocrinol Metab. 2012 Jan;97(1):41-8. doi: 10.1210/jc.2011-1679. Epub 2011 Nov 2. Review.

PMID:
22049171
30.

Myocardial structure, function, and scar in patients with type 1 diabetes mellitus.

Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, Liu CY, Lima JA, Bluemke DA; DCCT/EDIC Research Group.

Circulation. 2011 Oct 18;124(16):1737-46. doi: 10.1161/CIRCULATIONAHA.111.022327. Epub 2011 Sep 26.

31.

Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; BARI 2D Investigators.

Circulation. 2011 Aug 9;124(6):695-703. doi: 10.1161/CIRCULATIONAHA.110.014860. Epub 2011 Jul 18.

32.

Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S.

Ann Intern Med. 2011 Apr 19;154(8):554-9. doi: 10.7326/0003-4819-154-8-201104190-00007. Review.

PMID:
21502652
33.

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT.

N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.

34.

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group.

Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Erratum in: Lancet. 2010 Oct 30;376(9751):1466.

35.

Effects of medical therapies on retinopathy progression in type 2 diabetes.

ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ.

N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. Erratum in: N Engl J Med. 2011 Jan 13;364(2):190. N Engl J Med. 2012 Dec 20;367(25):2458.

36.

Effect of dexamethasone on oral glucose tolerance in healthy adults.

Abdelmannan D, Tahboub R, Genuth S, Ismail-Beigi F.

Endocr Pract. 2010 Sep-Oct;16(5):770-7. doi: 10.4158/EP09373.OR.

PMID:
20350917
37.

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group.

Diabetes Care. 2010 Jul;33(7):1578-84. doi: 10.2337/dc10-0125. Epub 2010 Mar 9.

38.

Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT).

Kern EF, Erhard P, Sun W, Genuth S, Weiss MF.

Am J Kidney Dis. 2010 May;55(5):824-34. doi: 10.1053/j.ajkd.2009.11.009.

39.

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S; ACCORD Investigators.

BMJ. 2010 Jan 8;340:b5444. doi: 10.1136/bmj.b5444.

40.

Development and validation of GFR-estimating equations using diabetes, transplant and weight.

Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, Kusek J, Greene T, Levey AS.

Nephrol Dial Transplant. 2010 Feb;25(2):449-57. doi: 10.1093/ndt/gfp510. Epub 2009 Sep 30.

41.

Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ.

Arch Intern Med. 2009 Jul 27;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.

42.

A randomized trial of therapies for type 2 diabetes and coronary artery disease.

BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE.

N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7.

43.

The UKPDS and its global impact.

Genuth S.

Diabet Med. 2008 Aug;25 Suppl 2:57-62. doi: 10.1111/j.1464-5491.2008.02504.x. Review.

PMID:
18717981
44.

Effects of intensive glucose lowering in type 2 diabetes.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT.

N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.

45.

A step backward--or is it forward?

Genuth S, Kahn R.

Diabetes Care. 2008 Jun;31(6):1093-6. doi: 10.2337/dc07-2407. No abstract available.

PMID:
18509143
46.

Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited.

Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group.

Diabetes. 2008 Apr;57(4):995-1001. doi: 10.2337/db07-1618. Epub 2008 Jan 25.

47.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):4i-20i. Epub 2007 Apr 12. Review.

PMID:
17599424
48.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
49.

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M; ACCORD Study Group.

Am J Cardiol. 2007 Jun 18;99(12A):103i-111i. Epub 2007 Apr 13.

PMID:
17599420
50.

Supplemental Content

Loading ...
Support Center